Immuneering (IMRX) Equity Average (2021 - 2024)
Historic Equity Average for Immuneering (IMRX) over the last 4 years, with Q3 2024 value amounting to $62.0 million.
- Immuneering's Equity Average fell 4339.85% to $62.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $62.0 million, marking a year-over-year decrease of 4339.85%. This contributed to the annual value of $100.2 million for FY2023, which is 2460.36% down from last year.
- As of Q3 2024, Immuneering's Equity Average stood at $62.0 million, which was down 4339.85% from $72.5 million recorded in Q2 2024.
- Immuneering's Equity Average's 5-year high stood at $157.1 million during Q4 2021, with a 5-year trough of $61.6 million in Q3 2021.
- Its 4-year average for Equity Average is $106.7 million, with a median of $106.4 million in 2023.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 10753.19% in 2022, then crashed by 4339.85% in 2024.
- Immuneering's Equity Average (Quarter) stood at $157.1 million in 2021, then decreased by 26.26% to $115.9 million in 2022, then fell by 16.03% to $97.3 million in 2023, then tumbled by 36.26% to $62.0 million in 2024.
- Its last three reported values are $62.0 million in Q3 2024, $72.5 million for Q2 2024, and $84.6 million during Q1 2024.